Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Nephros, Inc. on June 16, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol NEPH.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on three principal matters at the Annual Meeting:
- Election of Director: Lisa Nettis was elected to the Board of Directors for a three-year term expiring in 2028.
- For: 6,066,124
- Withheld: 84,178
- Broker Non-Votes: 2,654,001
- Ratification of Auditors: Stockholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- For: 8,663,982
- Against: 137,516
- Abstain: 2,805
- Broker Non-Votes: 0
- Executive Compensation: Stockholders approved the compensation of named executive officers on an advisory (non-binding) basis.
- For: 6,078,954
- Against: 41,762
- Abstain: 29,586
- Broker Non-Votes: 2,654,001
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the significant number of broker non-votes (2,654,001) recorded for the director election and executive compensation proposals.
- Confirm the tenure and background of the newly elected director, Lisa Nettis, whose term expires in 2028.
- Review the full proxy statement for details on the specific compensation packages approved for named executive officers.